Right On Brands, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Right On Brands, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $1.14M | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | $997.1K | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | $78.0K | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | $328.6K | Aug 4, 2021 |
| FY2020 | Mar 31, 2019 | $255.8K | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | $9.3K | Jul 30, 2019 |
| FY2018 | Mar 31, 2017 | $587 | Aug 13, 2018 |
| FY2017 | Mar 31, 2016 | $16.1K | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | $23.3K | Jul 22, 2016 |
| FY2015 | Mar 31, 2014 | $4.9K | Jul 13, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $605.5K | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | $440.0K | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | $21.3K | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | $21.3K | Aug 4, 2021 |
| FY2020 | Mar 31, 2019 | $86.9K | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | $1.9K | Jul 30, 2019 |
| FY2018 | Mar 31, 2017 | $587 | Aug 13, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $8.7K | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | ($257.0K) | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | ($1.85M) | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | ($3.48M) | Aug 4, 2021 |
| FY2020 | Mar 31, 2019 | ($6.09M) | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | ($804.1K) | Jul 30, 2019 |
| FY2018 | Mar 31, 2017 | ($2.94M) | Aug 13, 2018 |
| FY2017 | Mar 31, 2016 | ($50.9K) | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | ($71.0K) | Jul 22, 2016 |
| FY2015 | Mar 31, 2014 | ($106.7K) | Jul 13, 2015 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | ($135.9K) | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | ($55.7K) | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | ($401.4K) | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | ($947.2K) | Aug 4, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Mar 31, 2020 | $0 | Apr 1, 2021 |
| FY2020 | Mar 31, 2019 | $337 | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | $12.7K | Jul 30, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | ($66.1K) | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | ($150.7K) | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | ($203.0K) | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | ($683.0K) | Aug 4, 2021 |
| FY2020 | Mar 31, 2019 | ($873.6K) | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | ($524.8K) | Jul 30, 2019 |
| FY2018 | Mar 31, 2017 | ($172.3K) | Aug 13, 2018 |
| FY2017 | Mar 31, 2016 | ($24.7K) | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | ($16.5K) | Jul 22, 2016 |
| FY2015 | Mar 31, 2014 | ($52.3K) | Jul 13, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Mar 31, 2021 | $6.0K | Aug 4, 2021 |
| FY2021 | Mar 31, 2020 | $0 | Aug 4, 2021 |
| FY2020 | Mar 31, 2019 | $18.0K | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | ($1.3K) | Jul 30, 2019 |
| FY2018 | Mar 31, 2017 | $1.8K | Aug 13, 2018 |
| FY2017 | Mar 31, 2016 | $1.6K | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | $1.4K | Jul 22, 2016 |
| FY2015 | Mar 31, 2014 | $7.4K | Jul 13, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $206.8K | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | $234.1K | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | $236.6K | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | $237.4K | Aug 4, 2021 |
| FY2020 | Mar 31, 2019 | $357.2K | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | $3.05M | Jul 30, 2019 |
| FY2018 | Mar 31, 2017 | $181.9K | Aug 13, 2018 |
| FY2017 | Mar 31, 2016 | $31.9K | Jul 14, 2017 |
| FY2015 | Jul 10, 2015 | $61.1K | Jul 13, 2015 |
| FY2016 | Mar 31, 2015 | $61.1K | Jul 22, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $703.9K | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | $800.1K | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | $1.65M | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | $2.42M | Aug 4, 2021 |
| FY2020 | Mar 31, 2019 | $2.09M | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | $68.2K | Jul 30, 2019 |
| FY2018 | Mar 31, 2017 | $92.0K | Aug 13, 2018 |
| FY2017 | Mar 31, 2016 | $114.6K | Jul 14, 2017 |
| FY2016 | Mar 31, 2015 | $116.9K | Jul 22, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | ($521.5K) | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | ($590.4K) | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | ($1.43M) | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | ($2.18M) | Aug 4, 2021 |
| FY2021 | Mar 31, 2019 | ($1.73M) | Aug 4, 2021 |
| FY2020 | Mar 31, 2018 | $2.98M | Apr 1, 2021 |
| FY2019 | Mar 31, 2017 | $90.0K | Jul 30, 2019 |
| FY2018 | Mar 31, 2016 | ($82.8K) | Aug 13, 2018 |
| FY2015 | Jul 10, 2015 | ($55.8K) | Jul 13, 2015 |
| FY2017 | Mar 31, 2015 | ($55.8K) | Jul 14, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | ($15.76M) | Aug 16, 2023 |
| FY2022 | Dec 31, 2022 | ($15.77M) | Jul 11, 2022 |
| FY2023 | Mar 31, 2022 | ($15.77M) | Aug 16, 2023 |
| FY2022 | Mar 31, 2021 | ($15.51M) | Jul 11, 2022 |
| FY2021 | Mar 31, 2020 | ($13.66M) | Aug 4, 2021 |
| FY2020 | Mar 31, 2019 | ($10.19M) | Apr 1, 2021 |
| FY2019 | Mar 31, 2018 | ($4.10M) | Jul 30, 2019 |
| FY2018 | Mar 31, 2017 | ($3.30M) | Aug 13, 2018 |
| FY2017 | Mar 31, 2016 | ($358.5K) | Jul 14, 2017 |
| FY2015 | Jul 10, 2015 | ($307.6K) | Jul 13, 2015 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Mar 31, 2020 | $67.2K | Apr 1, 2021 |
| FY2020 | Mar 31, 2019 | $90.9K | Apr 1, 2021 |
| FY2020 | Mar 31, 2018 | $47.5K | Apr 1, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Mar 31, 2021 | $705.3K | Aug 4, 2021 |
| FY2020 | Mar 31, 2020 | $574.9K | Apr 1, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | 0 | Aug 16, 2023 |
| FY2023 | Mar 31, 2022 | 0 | Aug 16, 2023 |
| FY2019 | Mar 31, 2019 | 0 | Jul 30, 2019 |
| FY2019 | Mar 31, 2018 | 0 | Jul 30, 2019 |
| FY2014 | Mar 31, 2014 | 0 | Jul 7, 2014 |
| FY2014 | Mar 31, 2013 | 0 | Jul 7, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | 0 | Aug 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Mar 31, 2016 | 32.58M | Jul 22, 2016 |
| FY2015 | Jul 10, 2015 | 32.22M | Jul 13, 2015 |
| FY2016 | Mar 31, 2015 | 32.22M | Jul 22, 2016 |
| FY2015 | Mar 31, 2014 | 32.22M | Jul 13, 2015 |
| FY2014 | Mar 31, 2013 | 31.72M | Jul 7, 2014 |